Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back.

Alwan AF, Matti BF, Naji AS, Muhammed AH, Abdulsahib MA.

Leuk Lymphoma. 2014 Dec;55(12):2830-4. doi: 10.3109/10428194.2014.904508. Epub 2014 Apr 22.

PMID:
24628295
2.
3.

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.

Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G.

Drugs Aging. 2013 Aug;30(8):629-37. doi: 10.1007/s40266-013-0088-6.

PMID:
23681399
4.

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.

Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G.

Haematologica. 2014 Jul;99(7):1204-11. doi: 10.3324/haematol.2013.091272. Epub 2014 Feb 14.

5.

High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.

Petzer AL, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Stanchev A, Grubinger T, Kwakkelstein M, Schuld P, Gastl G, Wolf D.

Haematologica. 2012 Oct;97(10):1562-9. doi: 10.3324/haematol.2011.060087. Epub 2012 Apr 17.

6.

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.

Thielen N, van der Holt B, Verhoef GE, Ammerlaan RA, Sonneveld P, Janssen JJ, Deenik W, Falkenburg JH, Kersten MJ, Sinnige HA, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IW, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.

Ann Hematol. 2013 Aug;92(8):1049-56. doi: 10.1007/s00277-013-1730-4. Epub 2013 Apr 10.

PMID:
23572137
7.

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.

Cervantes F, López-Garrido P, Montero MI, Jonte F, Martínez J, Hernández-Boluda JC, Calbacho M, Sureda A, Pérez-Rus G, Nieto JB, Pérez-López C, Román-Gómez J, González M, Pereira A, Colomer D.

Haematologica. 2010 Aug;95(8):1317-24. doi: 10.3324/haematol.2009.021154. Epub 2010 Mar 10.

8.

Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil.

Silveira CA, Daldegan MB, Ferrari I.

Genet Mol Res. 2011 Sep 15;10(3):2038-48. doi: 10.4238/vol10-3gmr1073.

9.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators.

N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.

10.

[Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].

Voglová J, Poznarová A, Chrobák L, Rabasová J, Beránek M, Moravcová J, Faber E, Klamová H, Cikhart M.

Vnitr Lek. 2004 Jan;50(1):21-3, 26-9. Czech.

PMID:
15015226
11.

Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.

Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Akiyama H, Onishi S.

Int J Hematol. 2014 Feb;99(2):141-53. doi: 10.1007/s12185-013-1470-1. Epub 2013 Dec 20.

PMID:
24357015
12.

Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.

Breccia M, Latagliata R, Molica M, Colafigli G, Mancini M, Diverio D, Tafuri A, Alimena G.

Am J Hematol. 2015 May;90(5):E95-6. doi: 10.1002/ajh.23972. Epub 2015 Mar 30. No abstract available.

13.

Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.

Golabchifar AA, Rezaee S, Ghavamzadeh A, Alimoghaddam K, Dinan NM, Rouini MR.

Cancer Chemother Pharmacol. 2014 Jul;74(1):85-93. doi: 10.1007/s00280-014-2473-1. Epub 2014 May 10.

PMID:
24817601
14.

Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.

Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes T, Michor F, Paul J, Drummond M, Holyoake TL.

Br J Haematol. 2013 Dec;163(5):674-6. doi: 10.1111/bjh.12532. Epub 2013 Aug 19. No abstract available.

PMID:
24032404
15.
16.

Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase.

Jiang H, Chen SS, Jiang B, Jiang Q, Qin YZ, Lai YY, Huang XJ.

Ann Hematol. 2011 Jan;90(1):41-6. doi: 10.1007/s00277-010-1031-0. Epub 2010 Jul 29.

PMID:
20668855
17.

Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.

Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J.

Cancer. 2011 Mar 1;117(5):982-91. doi: 10.1002/cncr.25533. Epub 2010 Oct 19.

18.

[Therapeutic efficacy of imatinib mesylate (glivec) in chronic phase of myeloid leukemia].

Turkina AG, Khoroshko ND, Druzhkova GA, Zingerman BV, Zakharova ES, Chelysheva EIu, Vinogradova OIu, Domracheva EV, Zakharova AV, Kovaleva LG.

Ter Arkh. 2003;75(8):62-7. Russian.

PMID:
14520855
19.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators.

N Engl J Med. 2003 Mar 13;348(11):994-1004.

20.

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.

Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K, Ohyashiki K.

Haematologica. 2012 Jun;97(6):903-6. doi: 10.3324/haematol.2011.056853. Epub 2011 Dec 16.

Supplemental Content

Support Center